Navigation Links
Skin cancer study uncovers new tumor suppressor gene
Date:3/29/2009

e tumor samples. Nearly one-quarter of the tumors analyzed had at least one MMP gene mutation. Some mutations were found in as few as 3 percent of tumors, while more than 6 percent of tumors had mutations in MMP-8 and more than 7 percent had mutations in MMP-27, which codes for an enzyme very similar to MMP-8.

"We often talk about cancer as though it is one disease, and cancers do have many common denominators. But when we look at the DNA level, we see that different cancers have different genetic profiles, and so do different patients who have the same cancer," said the study's senior author, Yardena Samuels, Ph.D., an investigator in the Cancer Genetics Branch of the NHGRI's Division of Intramural Research.

Dr. Samuels and her collaborators followed up their DNA sequencing work with cell and animal studies to see whether MMP-8 mutations affect enzyme function. Strikingly, the researchers showed that five of the mutations reduced activity of the MMP-8 enzyme. The researchers next studied whether MMP-8 mutations promote activities related to cancer. Indeed, cells with MMP-8 mutations showed increased ability to multiply outside the constraints of normal cells, a hallmark of cancer development known as anchorage-independent growth. Likewise, cells with MMP-8 mutations had a greater ability to migrate -- a key aspect of cancer metastasis -- than normal cells.

The researchers found that mice injected with cells expressing normal MMP-8 did not develop skin ulcers, which are one of the most important measures of cancer aggression in melanoma. In contrast, mice injected with cells expressing mutated MMP-8 went on to develop ulcerations and metastases in their lungs.


'/>"/>

Contact: Raymond MacDougall
macdougallr@mail.nih.gov
301-402-0911
NIH/National Human Genome Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Getting down to cancer basics
2. Mayo Clinic researchers discover and manipulate molecular interplay that moves cancer cells
3. Scripps scientists find structure of a protein that makes cancer cells resistant to chemotherapy
4. New drug agent knocks out multiple enzymes in cancer pathway
5. Molecular fingerprints point the way to earlier cancer diagnosis and more targeted treatment
6. Lombardi research: Monoclonal antibodies primed to become potent immune weapons against cancer
7. Research yields potential target for cancer, wound healing and fibrosis
8. Lab-on-a-chip homes in on how cancer cells break free
9. TGens Dr. Von Hoff wins award for cancer research
10. Researchers identify genetic markers for aggressive head and neck cancer
11. Cancer: Another step towards medication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/18/2015)... Fingerprint Cards (FPC) has received an order for ... from one if its module partners. Deliveries are planned to ... the sensors will be used by smartphone manufacturers in ... amount to 740 MSEK to date. In addition to previously ... number of smaller orders not separately communicated amounting to more ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... (UC) College of Medicine have discovered the cause of ... vasospasm. , A constriction of the blood vessels in ... days following a massive brain bleed known as hemorrhagic ... stroke develop vasospasm, and 40 percent of them die ...
... nanoparticles in biomedical applications and consumer products has raised ... Scientists at the University of Michigan are addressing those ... cell membranes—enough to cause cell death in some cases—and ... inventing these sorts of materials, you need to be ...
... pet animal, are attractive to owners because of their vibrant ... what meets the eye. , For more than a century, ... pigments to produce their rainbow of plumage colors, but their ... researcher has uncovered the chemistry behind the colors of parrots, ...
Cached Biology News:Researchers discover molecule that causes secondary stroke 2Probing The Promise And Perils Of Nanoparticles 2Probing The Promise And Perils Of Nanoparticles 3Transport System Smuggles Medicines Into Brain 2Transport System Smuggles Medicines Into Brain 3
(Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
(Date:5/21/2015)... May 21, 2015 Tunnell Consulting, ... the firm as senior statistician and Principal, a position ... experience in the management and analysis of complex and ... chemical industries. , “We’re delighted to have Julia join ... data analytics,” said Dr. Philippe Cini, Group Vice President ...
(Date:5/20/2015)... MECHANICSBURG, Pa. , May 20, 2015 /PRNewswire/ ... announced that the Federal Trade Commission granted early ... (HSR) Antitrust Improvements Act of 1976, as amended, ... by MJ Acquisition Corporation, a joint venture that ... XII, L.P. As previously announced, MJ ...
(Date:5/20/2015)... 20, 2015  Haemonetics Corporation (NYSE: HAE ) ... CEO, will present at The Jefferies 2015 Global Healthcare ... June 1 st , 2015 at 8:30am Eastern time.  ... presentation live via webcast at: http://wsw.com/webcast/jeff88/hae ... HAE ) is a global healthcare company dedicated to ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... Study demonstrates ,Best buy in public health, LONDON, ... the ten years since its initiation, the international,effort to ... the world of one of its most debilitating diseases.,The ... 6.6 million,children from acquiring LF and stopped another 9.5 ...
... the U.S. Department of Energy (DOE) to commercialize cellulosic ethanol production ... ... 7, 2008-- POET, the largest producer of ethanol in the world, ... Department of Energy (DOE) to commercialize cellulosic ethanol production technology. A ...
... RVX, CALGARY, Oct. 7 /PRNewswire-FirstCall/ - Resverlogix ... in light of,the recent significant market drop of ... that the company fundamentals remain the same if,not ... business developments.,There is no reason for the price ...
Cached Biology Technology:LF Elimination Program Treats Over Half Billion People and Protects Millions More From Debilitating Disease 2LF Elimination Program Treats Over Half Billion People and Protects Millions More From Debilitating Disease 3LF Elimination Program Treats Over Half Billion People and Protects Millions More From Debilitating Disease 4POET Receives Additional $76 Million in Federal Funding For Commercialization of Cellulosic Ethanol 2
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
...
Recombinant Ovine IFN Tau. Active on sheep, cow, human and mouse cells. Activity: 5.7 x 10 7 u/mg...
... Thermo's Wellwash AC is the easiest ... and is provided with liquid level ... bottles. The integrated orbital shaker and ... excellent washing performance. The big bottle ...
Biology Products: